Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.KRRO · Entity 6388 | Director | June 11, 2024 | June 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date June 11, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.19 · Expires 2034-06-10 | Direct | 5,190 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 5,190 · Balance 5,190 F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2020 Filed Dec 9, 2020 22:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 8,848 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-20-031021 · form4.xml · derivative · entry 7 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,352 Underlying: Common Stock · 8,848 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 22:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,798 | $31.52 | $151,232.96 |
DisclosureSEC source: 0001127602-20-031021 · form4.xml · nonDerivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $31.015 to $31.595. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 22:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,050 | $30.96 | $125,388.00 |
DisclosureSEC source: 0001127602-20-031021 · form4.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,598 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $30.01 to $31. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 22:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 8,848 | $0.61 | $5,397.28 |
DisclosureSEC source: 0001127602-20-031021 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 22:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 4,666 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-20-031021 · form4.xml · derivative · entry 6 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,200 Underlying: Common Stock · 4,666 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 22:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,666 | $30.02 | $140,065.39 |
DisclosureSEC source: 0001127602-20-031021 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $30 to $30.215. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 22:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 4,666 | $0.61 | $2,846.26 |
DisclosureSEC source: 0001127602-20-031021 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 600 | $28.65 | $17,190.00 |
DisclosureSEC source: 0001127602-20-030426 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $28.56 to $29.02. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:40 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 15,114 | $27.90 | $421,680.60 |
DisclosureSEC source: 0001127602-20-030426 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $27.51 to $28.45. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 23:57 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,749 | $21.41 | $58,856.09 |
DisclosureSEC source: 0001127602-20-028050 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,514 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.03 to $21.97. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 23:57 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 12,965 | $20.68 | $268,116.20 |
DisclosureSEC source: 0001127602-20-028050 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,263 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $20.01 to $21.005. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:26 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,878 | $19.71 | $96,145.38 |
DisclosureSEC source: 0001127602-20-026530 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,228 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.29 to $19.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:26 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 10,838 | $18.87 | $204,513.06 |
DisclosureSEC source: 0001127602-20-026530 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,106 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.28 to $19.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:16 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 3,586 | $19.05 | $68,318.32 |
DisclosureSEC source: 0001127602-20-024702 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,944 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.78 to $19.225. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:16 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 12,128 | $18.40 | $223,155.20 |
DisclosureSEC source: 0001127602-20-024702 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,530 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.75 to $18.71. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 15,714 | $21.63 | $339,829.39 |
DisclosureSEC source: 0001127602-20-022915 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,658 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.31 to $21.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:59 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 15,714 | $22.45 | $352,832.73 |
DisclosureSEC source: 0001127602-20-020974 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,372 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $22.05 to $23.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:32 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 3,839 | $18.57 | $71,276.41 |
DisclosureSEC source: 0001127602-20-018891 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.15 to $19.00. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:40 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 11,875 | $17.91 | $212,653.94 |
DisclosureSEC source: 0001127602-20-018455 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,925 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.46 to $18.31. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:32 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 10,478 | $18.18 | $190,494.23 |
DisclosureSEC source: 0001127602-20-016284 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.00 to $18.60. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 5,239 | $16.19 | $84,834.60 |
DisclosureSEC source: 0001127602-20-015778 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,278 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $16.00 to $16.50. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:15 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 5,236 | $15.28 | $79,997.18 |
DisclosureSEC source: 0001127602-20-015183 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $15.06 to $15.61. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:02 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 729 | $16.35 | $11,919.44 |
DisclosureSEC source: 0001127602-20-014596 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,753 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $16.07 to $16.74. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 21:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,410 | $16.08 | $22,673.65 |
DisclosureSEC source: 0001127602-20-014490 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,482 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $16.00 to $16.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:29 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 3,100 | $16.00 | $49,600.00 |
DisclosureSEC source: 0001127602-20-014220 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,892 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $16.00 to $16.02. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 19:53 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 5,236 | $15.13 | $79,234.29 |
DisclosureSEC source: 0001127602-20-014027 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,992 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $14.73 to $15.465. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 242,500 | $0.00 Strike: $25.05 | $0.00 |
DisclosureSEC source: 0001127602-20-005635 · form4.xml · derivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,500 Underlying: Common Stock · 242,500 shares Expires 2030-02-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024 Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 20,787 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000899243-20-000051 · doc4.xml · derivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,647 Underlying: Common Stock · 20,787 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 36,590 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000899243-20-000051 · doc4.xml · derivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,866 Underlying: Common Stock · 36,590 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 20,787 | $0.61 | $12,680.07 |
DisclosureSEC source: 0000899243-20-000051 · doc4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 36,590 | $0.61 | $22,319.90 |
DisclosureSEC source: 0000899243-20-000051 · doc4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 20:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 96,361 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-028546 · doc4.xml · derivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,361 Underlying: Common Stock · 96,361 shares Expires 2029-04-16 F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 00:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionSeries B Preferred Stock · Derivative | 27,161 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025217 · doc4.xml · derivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,033 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 00:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionSeries A Preferred Stock · Derivative | 43,989 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025217 · doc4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 00:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionCommon Stock | 10,563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025217 · doc4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 01:45 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 714,413 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024838 · doc4.xml · derivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,413 Underlying: Common Stock · 714,413 shares Expires 2029-10-01 F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| April 17, 2019 Filed Oct 3, 2019 01:45 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 444,371 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-024838 · doc4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,371 Underlying: Common Stock · 444,371 shares Expires 2029-04-16 F1 · security: This transaction is being reported pursuant to Rule 16a-2(a), and the securities covered by such transaction were previously included on the Reporting Person's Form 3. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2019, and will be fully vested and exercisable on January 1, 2023. Read SEC document |
| April 17, 2019 Filed Oct 3, 2019 01:45 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 96,361 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-024838 · doc4.xml · derivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,361 Underlying: Common Stock · 96,361 shares Expires 2029-04-16 F1 · security: This transaction is being reported pursuant to Rule 16a-2(a), and the securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.